(UroToday.com) To conclude the rare tumors session at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 Virtual meeting, Dr. Julien Van Damme discussed fertility preservation in testis cancer patients. By way of background, Dr. Van Damme notes that testicular cancer is the most common cancer in men of reproductive potential, with a peak incidence between 15-35 years of age and an associated high survival rate. It is estimated that 50% of patients have impaired fertility at presentation, and 25% have azoospermia prior to treatment, with <1/3 of patients undergoing sperm banking prior to therapy. Gonadotoxic therapies cause an overall decrease in male fertility by 30% and there is currently no method to predict which patients will become azoospermic after treatment.1 As follows is a summary of the relationship between testicular cancer and infertility prior to treatment: